Literature DB >> 20129159

Bapineuzumab in Alzheimer's disease: where now?

Gordon K Wilcock.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20129159     DOI： 10.1016/S1474-4422(09)70359-X

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  5 in total

Review 1.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

Review 2.  Developing therapeutic approaches to tau, selected kinases, and related neuronal protein targets.

Authors:  Virginia M-Y Lee; Kurt R Brunden; Michael Hutton; John Q Trojanowski
Journal:  Cold Spring Harb Perspect Med       Date:  2011-09       Impact factor: 6.915

3.  Drug development in pediatric psychiatry: current status, future trends.

Authors:  John S March; Joerg M Fegert
Journal:  Child Adolesc Psychiatry Ment Health       Date:  2012-02-07       Impact factor: 3.033

4.  T cell mediated cerebral hemorrhages and microhemorrhages during passive Aβ immunization in APPPS1 transgenic mice.

Authors:  Melanie Meyer-Luehmann; J Rodrigo Mora; Matthew Mielke; Tara L Spires-Jones; Alix de Calignon; Ulrich H von Andrian; Bradley T Hyman
Journal:  Mol Neurodegener       Date:  2011-03-09       Impact factor: 14.195

5.  Machine learning prediction and tau-based screening identifies potential Alzheimer's disease genes relevant to immunity.

Authors:  Jessica Binder; Oleg Ursu; Cristian Bologa; Shanya Jiang; Nicole Maphis; Somayeh Dadras; Devon Chisholm; Jason Weick; Orrin Myers; Praveen Kumar; Jeremy J Yang; Kiran Bhaskar; Tudor I Oprea
Journal:  Commun Biol       Date:  2022-02-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.